Lab Lobby Readies Defense Against Medicare Cuts
This article was originally published in The Gray Sheet
The clinical laboratory community is readying itself to defend against the potential for substantial cuts in Medicare reimbursement for its services as the pressure to reduce the federal deficit grows.
You may also be interested in...
Berwick supporters write White House
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.